SMO and cancer: Moreover, to control the pathway activity, most of the studies till now have mainly focused to develop a drug which only inhibit single proteins, such as GLI (ligand dependent way) or PTCH1 or SMO in the membrane and may not be able to cure the cancers caused by some other intracellular proteins apart from sole mutation in GLI or PTCH1 or SMO.